相关实验视频

Updated: Sep 9, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

早期高效治疗与多发性硬化症升级治疗策略的效果

Hilde Norborg¹, Jan Harald Aarseth², Janne Mannseth³

¹Department of Clinical Medicine, University of Bergen, 5021, Bergen, Norway; Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.

Multiple sclerosis and related disorders

|August 31, 2025

概括

与治疗升级相比,早期启动多发性硬化症 (MS) 的高效治疗显著减少了复发和MRI病变. 这种方法还降低了MS患者治疗转换的需要.

科学领域:

神经学
免疫学
临床试验

背景情况:

在现实环境中评估多发性硬化症 (MS) 的治疗策略.
在2017年实施的新型多发性硬化症治疗指南之前和之后的结果比较.
评估早期高效治疗与升级治疗的有效性.

研究的目的:

为了比较MS的升级治疗策略 (ETS) 和高强度治疗策略 (HiTS) 的治疗结果.
分析治疗开始时间对疾病活动和治疗持续性的影响.
为优化多发性硬化症管理策略提供证据.

主要方法:

追溯队列研究,比较2013-2017年 (ETS) 和2018-2020年 (HiTS) 间诊断的患者.
使用考克斯比例危险回归分析复发时间,MRI病变和药物切换.
定义为疾病修饰疗法 (DMT) 治疗开始日期的基线.

主要成果:

与升级治疗策略 (ETS) 组相比,高强度治疗策略 (HiTS) 组的新复发风险降低了70% (HR=0. 30).
在HiTS组中,新的MRI病变 (T2或GD1+) 的风险降低了77% (HR=0. 23).
在诊断时启动高效治疗,将药物更换的风险降低了67% (HR=0. 33).

结论:

早期开始高效的MS治疗显著降低了临床和MRI确认的疾病活动的风险.
开始接受高效的MS治疗的患者需要更少的治疗修改.
这些发现支持在MS治疗中转向早期,密集的治疗模式.

关键词:

没有DMT 升级情况非常有效国家在现实世界生存分析治疗策略

更多相关视频

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

相关概念视频

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications